Aim Immunotech Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Hemispherx Biopharma, Inc. (to 2019)
5
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due May 14, 2027
- 1 fee due Oct 19, 2027The maintenance fee for Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity (US 9,315,538) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,943,147 | dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants In force · From the USPTO record | In force | From the USPTO record | |
| US 8,075,878 | Broad spectrum immune and antiviral gene modulation by oral interferon In force · From the USPTO record | In force | From the USPTO record | |
| US 8,075,877 | Broad spectrum immune and antiviral gene modulation by oral interferon In force · From the USPTO record | In force | From the USPTO record | |
| US 8,722,874 | Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity In force · From the USPTO record | In force | From the USPTO record | |
| US 9,315,538 | Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity In force · From the USPTO record | In force | From the USPTO record | |
| US 11,642,396 | Method of Reducing Antigenic Drift or Reassortment of Viruses in a Host Animal Using Alpha Interferon In force · High confidence | In force | High confidence | |
| US 11,813,279 | Compositions for Cancer Therapy and Methods In force · High confidence | In force | High confidence | |
| US 12,714,723 | Compositions and Methods for Cancer Therapy In force · High confidence | In force | High confidence | |
| US 11,813,281 | Methods for improving exercise tolerance in myalgic encephalomyelitis patients In force · From the USPTO record | In force | From the USPTO record | |
| US 12,102,649 | Methods and compositions for treating endometriosis In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 11: 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 1 no status recorded